India's trade ties with Israel have only strengthened in the years after 2019. The total value of trade rose to $10.5 billion on a rolling four-quarter basis in June 2023 from $5.5 billion in the same month in 2019, shows a Business Standard analysis of data from the Centre for Monitoring Indian Economy (CMIE). A rolling four-quarter number provides a comparable figure across different time periods.
The finance ministry on Tuesday issued a clarification on the issue of excise on drugs and medicines based on the retail price.
Indian medicine accounted for over 50 per cent of all drug seizures in Europe for intellectual property rights violation last year. Industry experts said this indicates the seriousness of the problem. This data was revealed in the recently-released 2009 report of the European Union on the customs enforcement activities of its member states.
With a view to preventing more of Rofecoxib-like episodes, experts have suggested that drug companies should disclose all the data on the adverse side effects before the drug is licensed.
Ranbaxy Laboratories is recalling 29,790 blister packs of anti-allergy drug in the US, manufactured by its arm Ohms Laboratories, due to defective packaging.
Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).
Drug firm Strides Acrolab on Tuesday said it is in a position to supply Oseltamivir Capsules, the only available medicine against Influenza A HINI virus (Swine Flu), to meet the demand both from domestic and overseas market.
Court rejects bid to introduce a linkage between regulatory approval of a medicine and its patent status.
With intermittent disruptions in the supply chain of raw materials from China, the Indian pharma industry has braced itself with bigger inventory. Even smaller drug makers are now carrying a month of buffer stock of key raw materials, said industry insiders. The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players. Shipments are critical for the Indian drug industry, which imports 70 per cent of its raw material from China.
For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
With 62 filings, domestic pharma companies have filed the maximum number of drug master filings with the US Food and Drug Administration in the July-September 2006 quarter.
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy's Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
"We have launched Oseltamivir brand, called Antiflu, which is the only flu medicine from India to be prequalified by World Health Organisation," Cipla's Chairman and Managing Director, Y K Hamied said.
Prices of various leading drug brands will come down by up to 80 per cent thanks to the newly-approved National Pharmaceutical Pricing Policy but at the same time it will hurt investment sentiments in the country's pharmaceutical sector, according to industry bodies.
To be called Central Drug Administration or National Drug Authority, it will have 10 sub-authorities to deal with areas like cosmetics, blood safety, medical equipment, etc.
The move comes in the backdrop of the failure of the health ministry's World Bank-sponsored National Pharmacovigilance Programme to generate sufficient ADRs from select medical colleges. The central government also intends to provide financial support to institutions to run such monitoring centres. The health ministry has asked the finance ministry to introduce a budgetary head specifically for ADR monitoring, to ensure sustained government funds for the project.
An Indian Biotech Company that is testing a novel anti-cancer drug on patients in Bangalore says it is not alarmed by the London trial where the use of a similar class of drug led to disastrous results.
These brands belong to about 320 drugs of leading Indian pharmaceutical companies. The Drug Controller General of India's (DCGI's) office feels that these have been launched without its approval.
Novartis's famed cancer drug, Glivec, will not get patent protection in India. The apex body on patent and trademark disputes, the Intellectual Property Appellate Board (IPAB), has ruled that the drug "lacks innovation" and the high price tag of Rs 120,000 per month per patient would be too high for the common man.
.jpg)
Global pharmaceutical firms have had a series of patent disputes with Indian makers of generic drugs and several recent Indian rulings have gone against the international giants.
After establishing its dominance in the export of bulk drugs (raw materials for medicine production) to India, the Chinese drug industry is exploring ways to enter the final frontier in drug production - the finished goods or formulation business - in the country.
A segment of drug companies such as tablet and capsule makers may benefit from the government's move to review polluting status of these companies, which may help them save costs on pollution control equipment.
The company has received final approval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules in 30 mg and 90 mg strengths from the United States Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
Ranbaxy Laboratories has received US Food and Drug Authority approval for Benazepril Hydrochloride, a high blood pressure drug.
The US subsidiary of Sun Pharmaceuticals, Caraco Pharmaceutical Laboratories, has received a warning letter from the Food and Drug Administration.
The Union Budget has proposed to extend concessional basic customs duty of 5 per cent with full exemption from excise/countervailing duty to six specified life-saving drugs and vaccines, even as the stress has been laid on vaccine security.
Unlike India, the US is a free-pricing market.
Cadila Healthcare Ltd said on Thursday, said German Remedies, a part of the Zydus Group, has launched Fludara Oral (Fludarabine) in the Indian market for the treatment of chronic lymphocytic leukemia.
The petitioner failed to bring in evidence against Ranbaxy, said Supreme Court.
